Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.

Haga SB, Moaddeb J, Mills R, Voora D.

Pharmacogenomics. 2017 Mar;18(4):327-335. doi: 10.2217/pgs-2016-0175. Epub 2017 Feb 22.

PMID:
28244804
2.

An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.

Voora D, Coles A, Lee KL, Hoffmann U, Wingrove JA, Rhees B, Huang L, Daniels SE, Monane M, Rosenberg S, Shah SH, Kraus WE, Ginsburg GS, Douglas PS.

Am Heart J. 2017 Feb;184:133-140. doi: 10.1016/j.ahj.2016.11.004. Epub 2016 Nov 15.

3.

Circulating extracellular vesicles containing miRNAs may have utility as early biomarkers for cardiac injury.

Doran B, Voora D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S60. No abstract available.

4.

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.

Friede K, Li J, Voora D.

Clin Chem. 2017 Jan;63(1):177-185. doi: 10.1373/clinchem.2016.255232. Epub 2016 Nov 18. Review.

PMID:
27864383
5.

Rationale and design of the SLCO1B1 genotype guided statin therapy trial.

Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, Musty M, Voora D.

Pharmacogenomics. 2016 Nov 3. [Epub ahead of print] No abstract available.

PMID:
27807988
6.

Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.

Voora D, Rao AK, Jalagadugula GS, Myers R, Harris E, Ortel TL, Ginsburg GS.

EBioMedicine. 2016 Sep;11:157-164. doi: 10.1016/j.ebiom.2016.08.021. Epub 2016 Aug 14.

7.

Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.

Voora D, Shah SH.

J Am Coll Cardiol. 2016 Mar 15;67(10):1211-3. doi: 10.1016/j.jacc.2016.01.022. No abstract available.

PMID:
26965543
8.

Genome-wide association study on progression of carotid artery intima media thickness over 10 years in a Chinese cohort.

Xie G, Myint PK, Voora D, Laskowitz DT, Shi P, Ren F, Wang H, Yang Y, Huo Y, Gao W, Wu Y.

Atherosclerosis. 2015 Nov;243(1):30-7. doi: 10.1016/j.atherosclerosis.2015.08.034. Epub 2015 Sep 5.

PMID:
26343869
9.

Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.

Rose JJ, Voora D, Cyr DD, Lucas JE, Zaas AK, Woods CW, Newby LK, Kraus WE, Ginsburg GS.

PLoS One. 2015 Jul 20;10(7):e0132259. doi: 10.1371/journal.pone.0132259. eCollection 2015 Jul 20.

10.

Gene Expression Signatures and the Spectrum of Coronary Artery Disease.

Friede KA, Ginsburg GS, Voora D.

J Cardiovasc Transl Res. 2015 Aug;8(6):339-52. doi: 10.1007/s12265-015-9640-6. Epub 2015 Jun 19. Review.

PMID:
26089288
11.

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.

Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators..

Eur Heart J. 2015 Aug 1;36(29):1901-12. doi: 10.1093/eurheartj/ehv116. Epub 2015 May 2.

PMID:
25935875
12.

SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.

Li JH, Suchindran S, Shah SH, Kraus WE, Ginsburg GS, Voora D.

Pharmacogenomics. 2015;16(5):449-58. doi: 10.2217/pgs.15.2.

13.

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015 Feb 9. Review.

14.

Module-based association analysis for omics data with network structure.

Wang Z, Maity A, Hsiao CK, Voora D, Kaddurah-Daouk R, Tzeng JY.

PLoS One. 2015 Mar 30;10(3):e0122309. doi: 10.1371/journal.pone.0122309. eCollection 2015 Mar 30.

15.

Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.

Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D.

J Pers Med. 2014 Mar 27;4(2):147-62. doi: 10.3390/jpm4020147.

16.

Expression quantitative trait locus analysis identifies novel genes for statin myopathy.

Voora D.

Circ Cardiovasc Genet. 2014 Apr;7(2):220-1. doi: 10.1161/CIRCGENETICS.114.000611. No abstract available.

17.

A freeze on tailored antiplatelet therapy?

Voora D, Becker RC.

Circulation. 2014 May 27;129(21):2088-90. doi: 10.1161/CIRCULATIONAHA.114.009930. Epub 2014 Apr 9. No abstract available.

18.

Platelet RNA as a novel biomarker for the response to antiplatelet therapy.

Voora D, Ginsburg GS, Akerblom A.

Future Cardiol. 2014 Jan;10(1):9-12. doi: 10.2217/fca.13.90. No abstract available.

PMID:
24344654
19.

Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery.

Kertai MD, Esper SA, Akushevich I, Voora D, Ginsburg GS, Stafford-Smith M, Grichnik K, Newman MF, Fontes ML, Smith P, Podgoreanu MV, Mathew JP; Cardiothoracic Anesthesia Research Endeavors (CARE) Group..

J Thorac Cardiovasc Surg. 2014 Apr;147(4):1368-1375.e3. doi: 10.1016/j.jtcvs.2013.09.067. Epub 2013 Nov 21.

20.

Delivering pharmacogenetic testing in a primary care setting.

Mills R, Voora D, Peyser B, Haga SB.

Pharmgenomics Pers Med. 2013 Sep 18;6:105-12. doi: 10.2147/PGPM.S50598. eCollection 2013 Sep 18.

Supplemental Content

Loading ...
Support Center